Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Pierre-Fabre-Galien

More Like This

PR Newswire associated0

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

PR Newswire associated0

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

PR Newswire associated0

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA

PR Newswire associated0

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

PR Newswire associated0

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

PR Newswire associated0

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founder of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)

RegenLab France Receives Prestigious EU-EIB Innovation Champion Award

PR Newswire associated0

Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations